Medicus Pharma Ltd (TSE:MDCX) has released an update.
Medicus Pharma Ltd has successfully closed its $4 million initial public offering in the U.S., with its shares and warrants now trading on Nasdaq. The company plans to use the proceeds to advance its clinical trials for treating basal cell carcinoma and explore other non-melanoma skin diseases. Maxim Group LLC and Brookline Capital Markets managed the offering, with the underwriter partially exercising its overallotment option.
For further insights into TSE:MDCX stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Tesla Stock
- ‘Breath of Fresh Air,’ Says Daniel Ives About Rivian Stock
- ‘It’s Not Too Late to Load Up,’ Says Analyst About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
